GSK vet Lepore named CEO of Flagship’s ProFound
Plus: CEO Simonian retiring as Syros reorganizes, and updates from Broken String, Repligen, AmbioPharm, BPGbio and LifeArc
John Lepore will become CEO-partner at Flagship Pioneering, while becoming CEO of portfolio company ProFound Therapeutics Inc. Lepore was most recently SVP, head of research at GSK plc (LSE:GSK; NYSE:GSK), where he held roles for 17 years. Founded in 2020 by Flagship, ProFound is exploring the “dark proteome” at the ribosome, with the goal of discovering new targets and therapeutics.
Nancy Simonian will retire as CEO of Syros Pharmaceuticals Inc. (NASDAQ:SYRS) on Dec. 1, amid a reorganization at the oncology company. Chief Commercial Officer and CBO Conley Chee will succeed Simonian, who will remain on the board. Syros is planning to reduce its workforce by 35% while prioritizing tamibarotene, which is in Phase III for higher-risk myelodysplastic syndrome and Phase II for acute myelogenous leukemia. Syros will stop further investment in SY-2101 to treat acute promyelocytic leukemia as well as in its preclinical programs. ...